Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Medicines register
Registers› Irish medicines ›ELOCTA 2000 IU powder and solvent for solution for injection
Medicines register · Ireland

ELOCTA 2000 IU powder and solvent for solution for injection

Authorisation EU/1/15/1046/006 · Swedish Orphan Biovitrum AB

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 19 Nov 2026
Licence holder
Swedish Orphan Biovitrum AB (all products →)
Active substance
Efmoroctocog alfa
Dosage form
Powder and solvent for solution for injection
Route of administration
Intravenous use
ATC codes
B02BD, B02BD02
First authorised
19/11/2015
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Full application (Article 8(3) of Directive No 2001/83/EC)

Efmoroctocog alfa: supply and approvals

8 authorised products on the HPRA list contain Efmoroctocog alfa. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 19 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 19 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 19 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 1046. It has been authorised for 11 years (since 19 November 2015). The HPRA list does not say whether it is on sale.

Open the European Commission’s Union Register record →

Other medicines with Efmoroctocog alfa in Ireland

7 other products on the HPRA list contain Efmoroctocog alfa, from 2 licence holders; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
ELOCTA 1000 IU powder and solvent for solution for injectionSwedish Orphan Biovitrum ABCentralised EU authorisationNot stated
ELOCTA 1500 IU powder and solvent for solution for injectionSwedish Orphan Biovitrum ABCentralised EU authorisationNot stated
ELOCTA 250 IU powder and solvent for solution for injectionSwedish Orphan Biovitrum ABCentralised EU authorisationNot stated
ELOCTA 3000 IU powder and solvent for solution for injectionSwedish Orphan Biovitrum ABCentralised EU authorisationNot stated
ELOCTA 4000 IU powder and solvent for solution for injectionSwedish Orphan Biovitrum AB(publ)Centralised EU authorisationNot stated
ELOCTA 500 IU powder and solvent for solution for injectionSwedish Orphan Biovitrum ABCentralised EU authorisationNot stated
ELOCTA 750 IU powder and solvent for solution for injectionSwedish Orphan Biovitrum ABCentralised EU authorisationNot stated

Other substances in ATC group B02BD

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 40 other active substances share the group B02BD with this product:

Octocog alfa (13) · Simoctocog alfa (11) · Recombinant coagulation fviii (octocog alfa) (9) · Human coagulation factor viii (9) · Lonoctocog alfa (7) · Nonacog alfa (6) · Turoctocog alfa (6) · Eftrenonacog alfa (5) · TUROCTOCOG ALFA PEGOL (5) · Nonacog gamma (5) · Rurioctocog alfa pegol (4) · Rix-fp (4) · Recombinant antihemophilic factor (4) · Moroctocog alfa (4) · Von willebrand factor (4) · Factor ii activity (3) · Factor vii activity (3) · Factor x activity (3) · Factor ix activity (3) · Protein c activity (3) · and 20 more

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Swedish Orphan Biovitrum AB holds 16 products on the HPRA list, with 5 different active substances; 0 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 20 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.